Eukaryotic translation initiation factor 5A2 is highly expressed in prostate cancer and predicts poor prognosis

Abstract

Eukaryotic translation initiation factor (EIF) 5A2 exerts important functions that regulate the development and progression of cancers. The present study aimed to investigate the expression of EIF5A2 in prostate cancer (PCa) and its association with biological and prognostic significance. EIF5A2 mRNA and protein levels were analyzed in three paired samples of freshly resected PCa and adjacent non-tumor tissues. Immunohistochemical staining was used to detect the expression of EIF5A2 protein levels in 72 paraffin-embedded PCa tumor specimens. Subsequently, the association between EIF5A2 protein expression and clinicopathological parameters was assessed. Semi-quantitative reverse transcription-polymerase chain reaction and western blot analyses showed both EIF5A2 mRNA and protein levels were elevated in PCa compared with adjacent non-tumor tissues. Elevated EIF5A2 protein levels were observed in 73.6% (53/72) of the clinical PCa tissues using immunohistochemical staining. EIF5A2 expression was significantly associated with tumor stage (P= 0.011) and biochemical recurrence status (P= 0.032). Additionally, high levels of EIF5A2 predicted worse progression-free survival (P= 0.007). Multivariate Cox regression analysis indicated that high expression of EIF5A2 was an independent prognostic factor for poor progression-free survival (hazard ratios, 0.366; 95% confidence interval, 0.349-0.460; P=0.021). The present study demonstrated that EIF5A2 is overexpressed in prostate cancer and may be a potential predictor and therapeutic target in PCa patients.

Overexpression of EIF5A2 Predicts Poor Prognosis in Patients with Oral Squamous Cell Carcinoma

“…Over the decades, hundreds of biomarkers have been investigated, including p53, Ki-67, p16, Cyclin D1, and VEGFs, with variable conclusions [ 7 ]. The eukaryotic translation initiation factor 5A2 (EIF5A2) expressing gene is located on chromosome 3q26, which is a location for many other oncogenes [ 8 , 9 , 10 ]. As a member of the EIF5A family, which promotes the initiation of mRNA translation, EIF5A2 is also involved in cell proliferation, apoptosis, and nuclear export [ 11 , 12 ].…”

“…Unlike most members of the EIF5A family that are universally expressed, EIF5A2 is tissue specific to the testis, brain, and tumor cells, especially in ovarian and colorectal cancer cell lines [ 9 , 13 ]. EIF5A2 has been reported to be associated with ovarian cancer, colorectal carcinoma, hepatocellular carcinoma, breast cancer, bladder cancer, non-small cell lung cancer, gastric cancer, prostate cancer, and nasopharyngeal carcinoma [ 8 , 9 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ].…”

Half Way to Hypusine—Structural Basis for Substrate Recognition by Human Deoxyhypusine Synthase

“…Hypusinated eIF5A is essential for tumour growth, and its level of expression is closely related to the aggressiveness of cancers [21]. Moreover, the expression of the latter eIF5A-2 variant is a hallmark of many cancers [22,23]. DHS (EC: 2.5.1.46) is a cytosolic transferase involved in the first enzymatic step of the unique post-translational modification of eIF5A.…”

Recent insights into eukaryotic translation initiation factors 5A1 and 5A2 and their roles in human health and disease

“…Expression of EIF5A2 also predicts poor prognosis of nasopharyngeal carcinoma patients [96], prostate cancer patients [97], and upper tract urothelial carcinoma patients [98], however the exact functions of eIF5A2 in these cancers should be further studied.…”

“…For EIF5A2, it acts as an oncogene in several cancers. Its high expression correlates with poor survival and aggressive tumor biology, including BC [76][77][78], cervical cancer [80], CRC [82,83], ESCC [26], GC [84], HCC [86], NSCLC [89], melanoma [92,93], ovarian carcinoma [94], nasopharyngeal carcinoma [96], prostate cancer [97], and upper tract urothelial carcinoma [98]. Altogether, both EIF5A1 and EIF5A2 are involved in the cancer development and progression, and can be a useful marker for diagnosis and prognosis.…”